Her-2 and targeted treatment for gastric cancer
10.3760/cma.j.issn.1673-422X.2011.09.014
- VernacularTitle:Her-2与胃癌的分子靶向治疗
- Author:
Mingxin LI
;
Zhonghe YU
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Targeted therapy;
Trastuzumab
- From:
Journal of International Oncology
2011;38(9):687-690
- CountryChina
- Language:Chinese
-
Abstract:
Her-2( human epidermal growth fact or receptor 2) is a type of 185 kD across the membrane glycoprotein with tyrosine kinase activity,play an important function in the cell divisions across a cell membrane proliferation signal transduction,and finally affect biological activities of tumor cells from multiple ways,such as a tumor cell proliferation and adhesion,transfer and differentiation and other related gene regulation.Recent studies show that Her-2 overexpression rate of gastric cancer patients is about 12％ ～ 35％,and Her-2 is a gastric cancer poor-prognostic factors,while Her-2 monoclonal antibody-Trastuzumab is expected to become a new standard gastric cancer treatment for the patients with Her-2 overexpressed.
